International Assessment of Biomanufacturing Engineering (BME)
              

         
 

Panel Chair



  Stephen Drew, Drew Solutions
 

Research Interests
Stephen W. Drew is a former Distinguished Senior Scientist at Merck & Co., Inc. where his responsibilities encompassed the development of new process technologies for biologics and pharmaceutical manufacturing and technology transfer. Since retirement from Merck, he has founded two new companies (Drew Solutions LLC, a direct consulting firm and Science Partners LLC, an advocacy company for medicines and technologies) that support the biotechnology and pharmaceutical industries. Prior to his retirement, he held vice presidential positions of responsibility at Merck & Co., Inc. as the VP of Vaccine Science and Technology, the VP of Vaccine Operations, and the VP of Technical Operations & Engineering. He joined Merck in 1981 to create the Department of Biochemical Engineering. At Merck, he contributed to the process development and manufacture of several conventional and recombinant microbial products ranging from antibiotics to vaccines. Dr. Drew has expertise in the following areas: manufacturing processes for human and animal vaccines; recombinant biologics; chemical, biological and engineering technology for bulk manufacture of pharmaceuticals and biologics; and fermentation, cell culture, isolation and purification processes for sterile products. Dr. Drew received his B.S. and an M.S. in food science from the University of Illinois, and a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (MIT). He was elected to the National Academy of Engineering in 1993 and is a member of several professional organizations serving interests in chemical engineering, chemistry and biology. He has served as Chairman of the advisory committee to the Engineering Directorate of the National Science Foundation. He is a member of two standing committees of the National Research Council (NRC) and has participated in many NRC studies.

Specialties: Vaccine development and manufacturing; biochemical engineering

<<back to home page

 

 

Panelists



  Gang Bao Gang Bao, Georgia Institute of Technology

Research Interests
  • Inverse and design problems in partial differential equations
  • Diffractive, nonlinear, near-field, and nano optics
  • Electromagnetic and acoustic wave propagation
  • Applied and numerical analysis
  • Multi-scale, multi-physics scientific computing

 

<<back to home page

 

  Chris Bettinger, Carnegie Mellon University

Research Interests
The Laboratory for Therapeutic Biodegradable Microsystems is broadly interested in the development of biomaterials-based MEMS for use in a wide range of biomedical applications including regenerative medicine, neural interfaces, and drug delivery. We use interdisciplinary strategies to develop next generation medical implants that combine extraordinary properties of biodegradability and biocompatibility with unique mechanical properties and electronic functionality.
Our laboratory is currently focused on several specific thrusts including: BioMEMS for tissue regeneration, biodegradable electronic devices, biomimetic tissue-device interfaces, non-conventional microfabrication of biomaterials, rational biomaterials synthesis, and quantitative elucidation of biodegradation phenomena.

 

<<back to home page   


 
Kam Leong, Duke University

 

Leong's research interest focuses on biomaterials design, particularly on synthesis of nanoparticles for DNA-based therapeutics, and nanostructured biomaterials for regenerative medicine.

<<back to home page

 

  Madhusudan V. Peshwa, MaxCyte
 

Madhusudan Peshwa, Ph.D., currently serves as Vice President, Research and Development at MaxCyte, Inc. Most recently, he was Executive Vice President for Research and Development at NewNeural LLC, a start-up stem cell therapy company. Earlier he served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN), where we was responsible for development, characterization and manufacture of an autologous dendritic cell vaccine product from concept to late Phase III pivotal studies. His expertise is in the areas of design, characterization, scale-up and implementation of processes, and cGMP systems in the development of engineered cell and tissue products and for biopharmaceuticals' production. Dr. Peshwa obtained his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 35 scientific publications and is a co-inventor on five, issued or under review, patent applications.

<<back to home page

 

  Kaiming Ye, Binghamton University
 

Research Interests
Dr. Ye main research focuses on turning a Beta Cell differentiation into a bio-function cell treatment to improve the glucose sensor, which he spent a couple of years developing and improving.
Diabetes patients are constantly monitoring glucose levels because they have no beta cells in the pancreas that can fend off disease. This dependence is a severe impediment, in many ways because everyday tasks are made difficult by the disease when, perhaps, they don’t have to be.
Ye’s research could lead to the end of diabetes. By recreating beta cells and transplanting them into patients’ bodies, the cells could create insulin in the body and eliminate the disease.


<<back to home page